The effect of pharmaceutical intervention on lipid profile in polycystic ovary syndrome.

Diamanti-Kandarakis, E; Kandaraki, E; Christakou, C; Panidis, D

Diamanti-Kandarakis, E; Kandaraki, E; Christakou, C; Panidis, D.

Affiliation

Diamanti-Kandarakis E; Division of Endocrinology, First Department of Medicine, Laiko Hospital, Medical School, University of Athens, Athens, Greece. akandara@otenet.gr

Obes Rev ; 10(4): 431-41, 2009 Jul.

Article in En | MEDLINE | ID: mdl-19413702

Subject(s)

Dyslipidemias/drug therapy; Hypolipidemic Agents/therapeutic use; Lipid Metabolism/drug effects; Polycystic Ovary Syndrome/drug therapy; Polycystic Ovary Syndrome/metabolism; Androgen Antagonists/therapeutic use; Contraceptives, Oral/therapeutic use; Dyslipidemias/complications; Dyslipidemias/metabolism; Female; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors/therapeutic use; Hyperandrogenism/complications; Hyperandrogenism/drug therapy; Hyperandrogenism/metabolism; Infertility, Female/drug therapy; Infertility, Female/etiology; Infertility, Female/metabolism; Insulin Resistance; Polycystic Ovary Syndrome/complications; Risk Factors

Fulltext

Add to My VHL

XML

PubMed Links

Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Polycystic Ovary Syndrome / Dyslipidemias / Lipid Metabolism / Hypolipidemic Agents Type of study: Etiology_studies / Risk_factors_studies Limits: Female / Humans Language: En Journal: Obes Rev Journal subject: METABOLISMO Year: 2009 Document type: Article Affiliation country: Greece Country of publication: United kingdom

Fulltext

Add to My VHL

XML

PubMed Links

Search on Google